中文

Hong Kong Stocks · Free Data Page

SH PHARMA 02607

SH PHARMA: FY2025 revenue CN¥283.6B (+3.00% YoY); net income CN¥5.72B; 0 alerts, 2 watch items out of 17 risk checks; TTM dividend HK$0.52/sh.
Close PriceHK$11.20Day +1.17%Market CapHK$41.53BP/E6.9xTTMP/B0.45xDividend Yield4.66%TTMROE (FY2025)7.8%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for SH PHARMA?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥120.8B in FY2016 to CN¥283.6B in FY2025 (9-year CAGR +9.9%).
  • Profitable in every fiscal year across 2016–2025.
  • Operating cash flow was below half of net income in FY2016, FY2017, FY2018.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)216232260275284
YoY12.5%7.5%12.2%5.7%3.0%
Net Income (CNY B)5.095.623.774.555.72
YoY13.3%10.3%-32.9%20.8%25.7%
Operating Cash Flow (CNY B)5.064.745.235.836.15
ROE10.8%9.6%5.6%6.5%7.8%
Gross Margin13.2%13.1%12.0%11.1%10.7%
Net Margin2.4%2.4%1.4%1.7%2.0%
Debt-to-Assets63.9%60.6%62.1%62.1%61.5%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)121131159187192216232260275284
YoY—8.3%21.6%17.3%2.9%12.5%7.5%12.2%5.7%3.0%
Net Income (CNY B)3.203.523.884.084.505.095.623.774.555.72
YoY—10.1%10.2%5.2%10.2%13.3%10.3%-32.9%20.8%25.7%
Operating Cash Flow (CNY B)1.221.641.606.026.845.064.745.235.836.15
ROE10.1%10.7%10.6%10.1%10.3%10.8%9.6%5.6%6.5%7.8%
Gross Margin11.5%12.4%13.6%14.4%13.9%13.2%13.1%12.0%11.1%10.7%
Net Margin2.6%2.7%2.4%2.2%2.3%2.4%2.4%1.4%1.7%2.0%
Debt-to-Assets—57.9%63.4%64.0%63.3%63.9%60.6%62.1%62.1%61.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 2Watch 15Pass

Items Flagged for Review

  • Watch

    GoodwillFinancial Quality

    CN¥12.65B, 15.9% of equity

    Q3 (2026-09-30) · What is this?

  • Watch

    Short-Term Debt CoverageSolvency

    Cash CN¥32.40B, short-term debt CN¥44.74B (0.72x)

    Q3 (2026-09-30) · What is this?

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.521 per share, or 4.66% yield at closing price; last full fiscal year: HK$0.537 (payout ratio 32.9%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.